Which anticholinergic drug for overactive bladder symptoms in adults

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

“…In our study, we also demonstrated that solifenacin prescribing has increased considerably, and is now the dominant OAB agent in Canada. This is likely due to evidence suggesting that solifenacin has improved clinical efficacy and fewer side effects compared to other commonly prescribed agents like tolterodine . Specifically, reviews of the literature have reported lower discontinuation rates due to adverse effects, fewer urgency episodes, and better patient reported quality of life among solifenacin users compared to alternatives such as fesoterodine, tolterodine, oxybutynin, and trospium .…”

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

“…In our study, we also demonstrated that solifenacin prescribing has increased considerably, and is now the dominant OAB agent in Canada. This is likely due to evidence suggesting that solifenacin has improved clinical efficacy and fewer side effects compared to other commonly prescribed agents like tolterodine . Specifically, reviews of the literature have reported lower discontinuation rates due to adverse effects, fewer urgency episodes, and better patient reported quality of life among solifenacin users compared to alternatives such as fesoterodine, tolterodine, oxybutynin, and trospium .…”

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis

“…The other meta-analysis, showed significant benefits for solifenacin compared with tolterodine ER or IR 4 mg/day in micturitions/24 h, urgency episodes/24 h, and incontinence episodes/24 h, although all solifenacin doses were combined in this analysis. 27 Also, as in our analysis, both meta-analyses showed that solifenacin 10 mg/day was more effective than solifenacin 5 mg/day in reducing micturitions/24 h but was associated with a significantly higher risk of dry mouth, 21,27 although the rates of constipation and blurred vision were similar with both doses in one meta-analysis. 27 Most previous meta-analyses comparing antimuscarinics in the treatment of OAB have used traditional methods, that is, included only studies which compare the same interventions.…”

“…The findings of superior effectiveness with solifenacin 5 mg/day compared with tolterodine 4 mg/day for reducing incontinence and UUI frequency concur with two other meta‐analyses . Madhuvrata et al reported significantly fewer leakage episodes/24 h and urgency episodes/24 h with solifenacin 5 mg/day versus tolterodine ER or IR 4 mg/day.…”

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

“…Because there were some significant benefits in the active arm, there is “ insufficient evidence” to make a conclusion on efficacy. The practice implications for solifenacin for the treatment of overactive bladder is “ possibly useful” as there were some significant benefits in this trial and because of the established efficacy and license of solifenacin in this indication outside PD . No safety concerns were reported.…”

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

“…In our study, we also demonstrated that solifenacin prescribing has increased considerably, and is now the dominant OAB agent in Canada. This is likely due to evidence suggesting that solifenacin has improved clinical efficacy and fewer side effects compared to other commonly prescribed agents like tolterodine . Specifically, reviews of the literature have reported lower discontinuation rates due to adverse effects, fewer urgency episodes, and better patient reported quality of life among solifenacin users compared to alternatives such as fesoterodine, tolterodine, oxybutynin, and trospium .…”

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis

“…The other meta-analysis, showed significant benefits for solifenacin compared with tolterodine ER or IR 4 mg/day in micturitions/24 h, urgency episodes/24 h, and incontinence episodes/24 h, although all solifenacin doses were combined in this analysis. 27 Also, as in our analysis, both meta-analyses showed that solifenacin 10 mg/day was more effective than solifenacin 5 mg/day in reducing micturitions/24 h but was associated with a significantly higher risk of dry mouth, 21,27 although the rates of constipation and blurred vision were similar with both doses in one meta-analysis. 27 Most previous meta-analyses comparing antimuscarinics in the treatment of OAB have used traditional methods, that is, included only studies which compare the same interventions.…”

“…The findings of superior effectiveness with solifenacin 5 mg/day compared with tolterodine 4 mg/day for reducing incontinence and UUI frequency concur with two other meta‐analyses . Madhuvrata et al reported significantly fewer leakage episodes/24 h and urgency episodes/24 h with solifenacin 5 mg/day versus tolterodine ER or IR 4 mg/day.…”

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

“…Because there were some significant benefits in the active arm, there is “ insufficient evidence” to make a conclusion on efficacy. The practice implications for solifenacin for the treatment of overactive bladder is “ possibly useful” as there were some significant benefits in this trial and because of the established efficacy and license of solifenacin in this indication outside PD . No safety concerns were reported.…”

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

“…In our study, we also demonstrated that solifenacin prescribing has increased considerably, and is now the dominant OAB agent in Canada. This is likely due to evidence suggesting that solifenacin has improved clinical efficacy and fewer side effects compared to other commonly prescribed agents like tolterodine . Specifically, reviews of the literature have reported lower discontinuation rates due to adverse effects, fewer urgency episodes, and better patient reported quality of life among solifenacin users compared to alternatives such as fesoterodine, tolterodine, oxybutynin, and trospium .…”

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis

“…The other meta-analysis, showed significant benefits for solifenacin compared with tolterodine ER or IR 4 mg/day in micturitions/24 h, urgency episodes/24 h, and incontinence episodes/24 h, although all solifenacin doses were combined in this analysis. 27 Also, as in our analysis, both meta-analyses showed that solifenacin 10 mg/day was more effective than solifenacin 5 mg/day in reducing micturitions/24 h but was associated with a significantly higher risk of dry mouth, 21,27 although the rates of constipation and blurred vision were similar with both doses in one meta-analysis. 27 Most previous meta-analyses comparing antimuscarinics in the treatment of OAB have used traditional methods, that is, included only studies which compare the same interventions.…”

“…The findings of superior effectiveness with solifenacin 5 mg/day compared with tolterodine 4 mg/day for reducing incontinence and UUI frequency concur with two other meta‐analyses . Madhuvrata et al reported significantly fewer leakage episodes/24 h and urgency episodes/24 h with solifenacin 5 mg/day versus tolterodine ER or IR 4 mg/day.…”

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

“…Because there were some significant benefits in the active arm, there is “ insufficient evidence” to make a conclusion on efficacy. The practice implications for solifenacin for the treatment of overactive bladder is “ possibly useful” as there were some significant benefits in this trial and because of the established efficacy and license of solifenacin in this indication outside PD . No safety concerns were reported.…”